Skoči na glavni sadržaj

Izvorni znanstveni članak

Prevalence and types of persistent dyslipidemia in patients treated with statins

Željko Reiner ; Department of Internal Medicine, University Hospital Center Zagreb, University of Zagreb School of Medicine, Zagreb, Croatia
Eugenia Tedeschi-Reiner ; Department of Ophthalmology University Hospital Center Sestre Milosrdnice, Zagreb, Croatia

Puni tekst: engleski pdf 148 Kb

str. 339-345

preuzimanja: 719



Aim To determine the prevalence and types of persistent
dyslipidemia in patients treated with different statins to
reduce cardiovascular disease (CVD) risk, as well as to determine
the proportion of high risk patients who did not
reach the lipid target values and assess cardiologists’ further
treatment advice for these patients.
Methods This cross-sectional, observational study recruited
1849 outpatients from all parts of Croatia between January
and September 2011 (44.6% women), 19 to 90 years
old (average age 63.13) treated with statins for at least 6
months. We analyzed how the potency and type of lipidlowering
treatment were correlated with CVD risk level and
achieving treatment goals according to 2007 Joint European
Guidelines on CVD prevention.
Results Most patients (81.3%) were at high risk for CVD.
The most frequently used statin was atorvastatin (42.8%),
followed by simvastatin (27.6%) and rosuvastatin (22.8%).
Only 35.5% patients achieved low density lipoproteincholesterol
treatment target. Patients treated with more
potent statins had better results. A total of 22.3% of patients
had high density lipoprotein-cholesterol below 1.0
mmol/L ( ~ 40 mg/dL) for men and below 1.2 ( ~ 45 mg/dL)
for women and 46.4% had triglycerides above 1.7 mmol/L
( ~ 150 mg/dL) but there were no significant differences between
statins in improving these parameters. Most of the
patients on more potent statins were not advised by their
cardiologists to change the type or dosage of statin, which
was more common in patients on less potent statins.
Conclusion A considerable number of patients treated
with statins did not achieve the treatment goal values. The
results were better in patients treated with more potent statins
and cardiologists advised them much less frequently
to change the type and dosage of statin. There is a need
for more intensive treatment, especially for high-risk patients.
This could be accomplished by optimizing patients’
adherence, using more potent statins, titrating current statin
therapy to higher doses, or using a combined lipid-lowering

Ključne riječi

Hrčak ID:



Datum izdavanja:


Posjeta: 1.289 *